INZY
Inozyme Pharma, Inc. [INZY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
INZY Stock Summary
In the News
INZY Financial details
Company Rating
-
Market Cap
317.51M
Income
-70M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
59
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-4.02
Forward P/E
-
PEG
1.88
P/S
-
P/B
1.65
P/C
-
P/FCF
-4.32
Quick Ratio
15.68
Current Ratio
16.36
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.36
EPS next Y
-
EPS next Q
-
EPS this Y
-20.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
20.69%
-
-
-
-
SMA20
-6.38%
SMA50
-50.38%
SMA100
-75.82%
Inst Own
-
Inst Trans
-
ROA
-32%
ROE
-54%
ROC
-0.37%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.689-7.795
52W High
-82.14%
52W Low
-37.5%
RSI
31.41
Rel Volume
1.09
Avg Volume
644.07K
Volume
705.24K
Perf Week
-3.1%
Perf Month
-55.67%
Perf Quarter
-77.11%
Perf Half Y
-75.63%
-
-
-
-
Beta
1.367
-
-
Volatility
0.04%, 0.29%
Prev Close
-1.57%
Price
1.25
Change
-4.58%
Company Profile
- Volume Average 644.07K
- Market Capitalization 317.51M
- Employee 59
- CEO Dr. Douglas A. Treco Ph.D.
- Headquarters Boston,MA,US
- IPO Date 2020-07-24
-
Website
https://www.inozyme.com 
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
